Last edition
News about "Evan Lippman"
Teva Plans Acquisition of Novel Neuroscience Product
Teva plans to acquire BXCL501, a novel dexmedetomidine sublingual film under the US Food and Drug Administration (FDA) review for potential at-home treatment of acute agitation in adults with schizophrenia or bipolar disorder.
Evan Lippman | 01/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members